The symptoms of Neurofibromatosis type-1 are a complex combination of genetic, environmental, and biological factors. It may cause high blood pressure, short stature, an abnormally large head, and scoliosis. Most affected individuals are otherwise normal in terms of their intelligence and overall health, though they may develop learning disabilities or attention-deficit/hyperactivity disorder.
The diagnosis of Neurofibromatosis type-1 involves genetic testing for SPRED1 mutations. The presence of a gene variation in this gene can be confirmed by clinical examination. A recent study in JAMA Netw Open cited a family member who had been diagnosed with the disorder. A genetic test for SPRED1 can help distinguish patients with neurofibromatosis from those without the gene variant.
In adults, there is a risk of blood cancer and brain cancer due to chances of developing cancerous tumor by Neurofibromatosis type-1 in some individuals. According to the National Library of Health report 2016, prevalence of Neurofibromatosis type-1 is 1 out of 3,000 to 4,000 individuals worldwide. Neurofibromatosis type-1 is treated depending upon its symptoms such as bony lesions, brain tumors, dermal neurofibromas, learning disabilities, plexiform tumors, vascular complication, and malignant peripheral nerve sheath tumors.
Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables& Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-pdf/4149
Global Neurofibromatosis type-1 Market Drivers
Increasing research &developments in the field of Neurofibromatosis type-1 as it is associated with various symptoms such as bony lessions, brain tumors, dermal neurofibromas, learning disabilities, plexiform tumors, vascular complication and malignant peripheral nerve sheath tumors is driving market growth. This creates a wide array of scope for pharmaceutical companies for research and development in the treatment of Neurofibromatosis type-1 based upon its symptoms. For instance, in April 2020, the U.S. Food Drug and Administration approved Koselgu (selumetinib) drug of AstraZeneca PLC and Merck & Co., Inc for the treatment of Neurofibromatosis type-1 associated with cancerous tumors.
Additionally, increasing focus of research institutes on research and development for the treatment of neurofibromatosis type-1 conditions is again fostering market growth. For instance, in 2018, University of Albama, in Brimingham completed the clinical trials on usage of drug lovastatin in neurofibromatosis type-1. These factors are expected to drive growth of the global Neurofibromatosis type-1 market over the forecast period.
Global Neurofibromatosis type-1 market COVID-19 Impact Analysis
Since the outbreak of COVID-19 pandemic every industry and sector around the world is affected negatively. Also, in the case of global Neurofibromatosis type-1 market, plexiform tumors are form of neurofibromatosis type-1, which are treated with help of chemotherapy and radiation therapy, which weakens the immune system of patients during the therapy. Thus, there is high risk of COVID-19 infections to patients suffering from plexiform tumors and undergoing its treatment. Furthermore, imposed safety precautions to prevent spread of COVID-19 infection has lead complications in carrying out chemotherapy and radiation therapy in the treatment of Neurofibromatosis type-1.
To Get more information Request for Free Sample Report at @ https://www.coherentmarketinsights.com/insight/request-sample/4149
Global Neurofibromatosis type-1 Market Restraints
Radiation therapy which is used for the treatment of neurofibromatosis leads to damaging of surrounding tissue of targeted tumors, and further leads to damaging of good blood cells. This is expected to hinder market growth. Additionally, inability to kill tumor cells which are not able to see in scans is a limitation in radiation therapy. Furthermore, chemotherapy may include late effects such as heart problems and reduced lung capacity. These factors are projected to hinder growth of the global Neurofibromatosis type-1 market.
Global Neurofibromatosis type-1 Market Regional Analysis
On basis of region, global Neurofibromatosis type-1 market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. In North America, pharmaceutical companies are focusing on new approaches to develop treatment for rare diseases such as Neurofibromatosis type-1 in the region. For instance, in June 2020, Nflection Therapeutics received US$ 20 million funding from series A financing round by Venbio Partners and F-prime Capitals and also announced initiation of clinical trials of NFX-179 gel, uses topical route for the treatment of Neurofibromatosis type-1.
Europe is projected to experience significant growth in the global neurofibromatosis type-1 treatment market, owing to increasing focus of pharmaceutical companies on mergers and acquisitions for the treatment of Neurofibromatosis type-1 and to strengthen their market position. For instance, in April 2020, Healx, an AI driven pharmaceutical company, entered into a partnership with Global Children’s Tumor Foundation (CTF) for development in the treatment of Neurofibromatosis type-1 genetic diseases.
Global Neurofibromatosis type-1 Market Key Players
Key operating players in global neurofibromatosis type-1 market include Merck & Co., Inc, AstraZeneca PLC, NFlection Therapeutics, Healx, and GL Pharm Tech Corporation.
On the basis of drug class, the global Neurofibromatosis type-1 market is segmented into:
On the basis of distribution channel, the global Neurofibromatosis type-1 market is segmented into:
- Hospital Pharmacies
- Retail Pharmacies
On the basis of region, the global Neurofibromatosis type-1 market is segmented into:
- North America
- Latin America
- Asia Pacific
- Middle East
Purchase This Premium Report With Flat USD 2000 OFF @ https://www.coherentmarketinsights.com/promo/buynow/4149
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027